HROW:NASDAQ
Harrow Inc
$30.58
arrow_upward
+0.33%(+0.10) 1D
$30.58
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 5, 4:00:02 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HROW...
Open
$31.43
High
$31.43
Low
$30.43
Mkt. cap
1.15B
Avg. vol.
538.19K
Volume
587.04K
52-wk high
$54.85
52-wk low
$28.54
EPS
-$1.00
Beta
0.19
Shares outstanding
37.49M
No. of employees
373
Open
$31.43
High
$31.43
Low
$30.43
Mkt. cap
1.15B
Avg. vol.
538.19K
Volume
587.04K
52-wk high
$54.85
52-wk low
$28.54
EPS
-$1.00
Beta
0.19
Shares outstanding
37.49M
No. of employees
373
News stories
From web sources and news partners
The Business Journals
·
1 hour ago
Harrow invests $30 million in new pharmaceutical as it builds portfolio
AD HOC NEWS
·
2 hours ago
Harrow Health stock gets TYRVAYA after USD 30 million deal
TipRanks
·
8 hours ago
Harrow Closes TYRVAYA Acquisition, Expanding Dry Eye Portfolio
Profile
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
About Harrow Inc
CEOMark L. Baum Esq.
Employees373
Founded2012
HeadquartersNashville, Tennessee, United States
SectorPharmaceutical industry
Websiteharrow.com